274 related articles for article (PubMed ID: 11479629)
1. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.
Ichikawa K; Liu W; Zhao L; Wang Z; Liu D; Ohtsuka T; Zhang H; Mountz JD; Koopman WJ; Kimberly RP; Zhou T
Nat Med; 2001 Aug; 7(8):954-60. PubMed ID: 11479629
[TBL] [Abstract][Full Text] [Related]
2. Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells.
Kaliberov S; Stackhouse MA; Kaliberova L; Zhou T; Buchsbaum DJ
Gene Ther; 2004 Apr; 11(8):658-67. PubMed ID: 14973547
[TBL] [Abstract][Full Text] [Related]
3. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.
Nagane M; Pan G; Weddle JJ; Dixit VM; Cavenee WK; Huang HJ
Cancer Res; 2000 Feb; 60(4):847-53. PubMed ID: 10706092
[TBL] [Abstract][Full Text] [Related]
4. Distinct function of monoclonal antibody to TRAIL-R2 as potentiator or inhibitor of the ligand TRAIL-induced apoptosis.
Mori E; Thomas M; Motoki K; Kataika S
FEBS Lett; 2005 Oct; 579(24):5379-84. PubMed ID: 16199041
[TBL] [Abstract][Full Text] [Related]
5. Cholestasis increases tumor necrosis factor-related apoptotis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity.
Higuchi H; Bronk SF; Taniai M; Canbay A; Gores GJ
J Pharmacol Exp Ther; 2002 Nov; 303(2):461-7. PubMed ID: 12388624
[TBL] [Abstract][Full Text] [Related]
6. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
[TBL] [Abstract][Full Text] [Related]
7. Role of tumor necrosis factor-related apoptosis-inducing ligand in immune response to influenza virus infection in mice.
Ishikawa E; Nakazawa M; Yoshinari M; Minami M
J Virol; 2005 Jun; 79(12):7658-63. PubMed ID: 15919918
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation.
Shigeno M; Nakao K; Ichikawa T; Suzuki K; Kawakami A; Abiru S; Miyazoe S; Nakagawa Y; Ishikawa H; Hamasaki K; Nakata K; Ishii N; Eguchi K
Oncogene; 2003 Mar; 22(11):1653-62. PubMed ID: 12642868
[TBL] [Abstract][Full Text] [Related]
9. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells.
Nakata S; Yoshida T; Horinaka M; Shiraishi T; Wakada M; Sakai T
Oncogene; 2004 Aug; 23(37):6261-71. PubMed ID: 15208660
[TBL] [Abstract][Full Text] [Related]
11. Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector.
Rubinchik S; Yu H; Woraratanadharm J; Voelkel-Johnson C; Norris JS; Dong JY
Cancer Gene Ther; 2003 Nov; 10(11):814-22. PubMed ID: 14605667
[TBL] [Abstract][Full Text] [Related]
12. [Correlation between sensitivity to TRAIL and expression level of DR5 on surface of tumor cells].
Ma YF; Zhang J; Zhao YP; Yang DL; Chen YH
Zhonghua Zhong Liu Za Zhi; 2004 Sep; 26(9):528-30. PubMed ID: 15555281
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
Straughn JM; Oliver PG; Zhou T; Wang W; Alvarez RD; Grizzle WE; Buchsbaum DJ
Gynecol Oncol; 2006 Apr; 101(1):46-54. PubMed ID: 16271751
[TBL] [Abstract][Full Text] [Related]
14. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639
[TBL] [Abstract][Full Text] [Related]
15. Eradication of established tumors in mice by a combination antibody-based therapy.
Uno T; Takeda K; Kojima Y; Yoshizawa H; Akiba H; Mittler RS; Gejyo F; Okumura K; Yagita H; Smyth MJ
Nat Med; 2006 Jun; 12(6):693-8. PubMed ID: 16680149
[TBL] [Abstract][Full Text] [Related]
16. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
Chen X; Kandasamy K; Srivastava RK
Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
[TBL] [Abstract][Full Text] [Related]
17. Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases.
Saitou Y; Shiraki K; Fuke H; Inoue T; Miyashita K; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Hum Pathol; 2005 Oct; 36(10):1066-73. PubMed ID: 16226105
[TBL] [Abstract][Full Text] [Related]
18. Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway.
He Q; Lee DI; Rong R; Yu M; Luo X; Klein M; El-Deiry WS; Huang Y; Hussain A; Sheikh MS
Oncogene; 2002 Apr; 21(17):2623-33. PubMed ID: 11965535
[TBL] [Abstract][Full Text] [Related]
19. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice.
Hao C; Song JH; Hsi B; Lewis J; Song DK; Petruk KC; Tyrrell DL; Kneteman NM
Cancer Res; 2004 Dec; 64(23):8502-6. PubMed ID: 15574753
[TBL] [Abstract][Full Text] [Related]
20. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.
van der Sloot AM; Tur V; Szegezdi E; Mullally MM; Cool RH; Samali A; Serrano L; Quax WJ
Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8634-9. PubMed ID: 16731632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]